ArticleApplied microbiology and biotechnology2018
n-Butanol production in S. cerevisiae: co-ordinate use of endogenous and exogenous pathways.
Article in Applied microbiology and biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 38 citations in OpenAlex.
- Metabolic engineering of Parageobacillus thermoglucosidasius for thermophilic production of 1-butanol.AMB Express · 2025Article
- Genetic engineering of non-native hosts for 1-butanol production and its challenges: a review.Microbial cell factories · 2020Review
- Butanol production by Saccharomyces cerevisiae: perspectives, strategies and challenges.World journal of microbiology & biotechnology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
n-Butanol represents a key commodity chemical and holds significant potential as a biofuel. It can be produced naturally by Clostridia species via the ABE pathway. However, butanol production via such systems can be associated with significant drawbacks. Therefore, substantial efforts have been made toward engineering a suitable industrial host for butanol production. For instance, we previously generated a metabolically engineered Saccharomyces cerevisiae strain that produces ~300 mg/L butanol from combined endogenous and exogenous pathways. In this current study, the endogenous and exogenous pathways of butanol production were further characterised, and their relative contribution to the overall butanol titre was assessed. Deletion of any single component of the exogenous ABE pathway was sufficient to significantly reduce butanol production. Further evidence for a major contribution from the ABE pathway came with the discovery that specific yeast deletion mutants only affected butanol production from this pathway and had a significant impact on butanol levels. In previous studies, the threonine-based ketoacid (TBK) pathway has been proposed to explain endogenous butanol synthesis in ADH1 mutants. However, we find that key mutants in this pathway have little impact on endogenous butanol production; hence, this pathway does not explain endogenous butanol production in our strains. Instead, endogenous butanol production appears to rely on glycine metabolism via an α-ketovalerate intermediate. Indeed, yeast cells can utilise α-ketovalerate as a supplement to generate high butanol titres (> 2 g/L). The future characterisation and optimisation of the enzymatic activities required for this pathway provides an exciting area in the generation of robust butanol production strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.